Literature DB >> 30653258

Gut-brain axis and the spread of α-synuclein pathology: Vagal highway or dead end?

David P Breen1,2,3, Glenda M Halliday4,5,6, Anthony E Lang7,8.   

Abstract

Spread of α-synuclein pathology from the peripheral to central nervous system may be an important etiological factor in Parkinson's disease, although there are some unanswered questions about its correlation with neuronal loss. Experimental evidence has highlighted the gastrointestinal tract as a potential starting point for aggregated α-synuclein, with the vagus nerve acting as a "highway" by which pathology may be transmitted to the lower brain stem. This review begins by highlighting the key studies demonstrating that α-synuclein pathology has the ability to spread from certain sites in the gastrointestinal tract to the brain (and vice versa). We go on to assess the recent epidemiological studies that have shown that vagotomy and appendectomy may have the potential to reduce the risk of developing Parkinson's disease. Finally, we discuss the factors in the gastrointestinal tract (such as dysbiosis of the gut microbiota, infection, and inflammation) that may trigger α-synuclein aggregation in the first place, as well as other potential mechanisms underlying the distribution of α-synuclein pathology in the brain.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  gut; peripheral; prion; vagus nerve; α-synuclein

Year:  2019        PMID: 30653258     DOI: 10.1002/mds.27556

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  45 in total

1.  Past appendectomy may be related to early cognitive dysfunction in Parkinson's disease.

Authors:  Alexandra R Gonçalves; Alexandre Mendes; Nuno Vila-Chã; Joana Damásio; Joana Fernandes; Sara M Cavaco
Journal:  Neurol Sci       Date:  2020-06-11       Impact factor: 3.307

Review 2.  α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.

Authors:  Michael X Henderson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neurosci Lett       Date:  2019-06-03       Impact factor: 3.046

3.  Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.

Authors:  Zachary D Wallen; Mary Appah; Marissa N Dean; Cheryl L Sesler; Stewart A Factor; Eric Molho; Cyrus P Zabetian; David G Standaert; Haydeh Payami
Journal:  NPJ Parkinsons Dis       Date:  2020-06-12

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 5.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

6.  Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes.

Authors:  Amnon A Berger; Ariel Winnick; Jonathan Izygon; Binil M Jacob; Jessica S Kaye; Rachel J Kaye; Elisa E Neuchat; Adam M Kaye; Edward S Alpaugh; Elyse M Cornett; Andrew H Han; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-06-28

Review 7.  Inflammatory Animal Models of Parkinson's Disease.

Authors:  Juan García-Revilla; Antonio J Herrera; Rocío M de Pablos; José Luis Venero
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 8.  Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.

Authors:  Vinod Metta; Valentina Leta; Kandadai Rukmini Mrudula; L K Prashanth; Vinay Goyal; Rupam Borgohain; Guy Chung-Faye; K Ray Chaudhuri
Journal:  J Neurol       Date:  2021-04-21       Impact factor: 4.849

Review 9.  The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability.

Authors:  Christine Girges; Nirosen Vijiaratnam; Dilan Athauda; Grace Auld; Sonia Gandhi; Thomas Foltynie
Journal:  Drugs Aging       Date:  2021-03-19       Impact factor: 3.923

10.  Oral Dysbiosis and Inflammation in Parkinson's Disease.

Authors:  Vanessa Fleury; Alkisti Zekeridou; Vladimir Lazarevic; Nadia Gaïa; Catherine Giannopoulou; Laurence Genton; José Cancela; Myriam Girard; Rachel Goldstein; Julien F Bally; Andrea Mombelli; Jacques Schrenzel; Pierre R Burkhard
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.